See the Glossary for more terms.
Concepts represent early planning stages for program announcements, request for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to the Opportunities and Announcements portal.
NB: Council approval does not guarantee that a concept will become an initiative.
Request for Applications
Contact: Francesca Macchiarini
Objective: To maintain a network of national research centers to develop effective and comprehensive medical countermeasures applicable to all subsets of the civilian population in the event of radiological or nuclear emergencies. Multidisciplinary basic and translational research will 1) produce new techniques and devices to measure radiation exposure in the human body and follow biomarkers of tissue damage and recovery and 2) develop novel therapies to minimize tissue damage, hasten tissue recovery, restore normal physiological function, and improve survival.
Description: The Centers for Medical Countermeasures Against Radiation (CMCR) will operate in a flexible, cooperative, and multidisciplinary manner to provide comprehensive research support to develop medical products for the civilian population. These products will assess, diagnose, mitigate, and/or treat the short- and long-term consequences of radiation exposure after a radiological/nuclear incident. The overall program is designed for optimal research flexibility, synergy, and efficiency with the goal of rapidly developing effective countermeasures for clinical use. When appropriate and in accordance with NIH policies (NIH Data Sharing Policy and Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources: Final Notice), awardees will be expected to collaborate and share novel reagents, assays, and animal models, as well as share positive and negative results to help guide the research and development activities of other CMCR network members.
This program will support both basic and translational research in the following research areas:
Broad Agency Announcement
Contact: Emily Dubbaneh
Objective: The purpose of this solicitation is to invite investigator-initiated proposals for continued development of new or existing approaches to treat and/or mitigate radiation-induced lung injury due to a nuclear or radiation incident. Radiation exposure type, dose level, and dose rates proposed for study would be those that would be relevant following a terrorist incident or accidental exposure.
Description: The focus of the solicitation will be applied and translational research to accelerate the development of safe and effective medical products to mitigate and/or treat pulmonary injury arising from exposure to ionizing radiation from a radiological or nuclear incident, thereby leading to a reduction in lung-associated morbidities that can impact survival (e.g., pneumonitis and/or fibrosis). Countermeasures of interest may include novel or known drugs to mitigate and/or treat radiation-induced lung tissue damage when administered 24 hours or later after exposure. It is anticipated that research and development studies awarded from this BAA will advance medical countermeasures toward submission of an investigational new drug (IND) application and eventual FDA approval for reducing major morbidities and/or increased survival after radiation exposure under the FDA Animal Rule (21 CFR 314.600-314.650, 601.90-601.95). Infrastructure improvements would be limited to small equipment purchases necessary to upgrade existing laboratories.
Request for Proposals
Contact: Deborah Blyveis
Objective: To provide additional funds to continue and expand nonclinical and clinical efforts for product development of radiation and nuclear medical countermeasure candidate drugs and biodosimetry devices for inclusion in the Strategic National Stockpile for use during a radiation emergency.
Description: The initiative will provide funds to continue and expand the development of radiation countermeasures for the Radiation and Nuclear Countermeasures Program. The program will provide a comprehensive and broad range of nonclinical and clinical support services that will be available to organizations (companies, government, academic, and Centers for Medical Countermeasures Against Radiation) that have promising medical countermeasure candidates. The program will support product development efforts for licensure of both candidate drugs and biodosimetry devices. The types of product development support services include screening and efficacy evaluation of candidate drugs, Good Laboratory Practice (GLP) toxicology and safety pharmacology in animal models, current Good Manufacturing Practice (cGMP) manufacturing support, GLP pivotal animal efficacy studies, phase I clinical safety and pharmacokinetic studies, and regulatory submission support for candidate drugs and biodosimetry devices.
Last Updated February 13, 2014
Last Reviewed February 13, 2014